According to the report the trend is for pharma companies to engage contract research organizations (CRO) and contract development and manufacturing organizations (CDMO) as well as other suppliers “to cover nearly every aspect of drug development from target identification to clinical-trial execution.”
Better efficiency and, importantly for our audience, improved